Searching…
2026年3月24日 · RO7497987 consists of a wild-type truncated extracellular domain of human FLT3L and an effectorless Fc portion of human IgG1 isotype (NG2LH) which are genetically fused from the C …
RO7497987 consists of a wild-type truncated extracellular domain of human FLT3L and an effectorless Fc portion of human IgG1 isotype (NG2LH) which are genetically fused from the C-terminus of FLT3L …
A Phase 1a, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RO7497987 in single and multiple ascending doses in healthy volunteers
RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC.MethodsThis Phase Ia trial evaluated the safety, tolerability, …
2025年7月5日 · The improved properties of FLT3L-Fc NG2LH are expected to mitigate the practical limitations of FLT3L usage in the clinic, and constitute an asset for future cancer immunotherapy …
A study to look at how safe different doses of RO7497987 were for healthy people to take – and how this medicine was processed through the body A Phase IA, open-label study to evaluate the safety, …
RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC.MethodsThis Phase Ia trial evaluated the safety, tolerability, …
The human OCI-AML5 cell line has been reported to proliferate in response to stimulation with human FLT3L. 48, 49, 50 FLT3L-Fc NG2LH and wild-type human FLT3L induced similar dose dependent …
2025年8月1日 · The human OCI-AML5 cell line has been reported to proliferate in response to stimulation with human FLT3L. 48, 49, 50 FLT3L-Fc NG2LH and wild-type human FLT3L induced …
2024年2月1日 · FLT3L-Fc is a fusion protein that links the wild-type, truncated extracellular domain of human FLT3L with the fragment crystallizable (Fc) portion of human immunoglobulin G1 (hIgG1) to …
